Experienced in an array of financial and administrative matters, Peter Culpepper facilitates the growth of Provectus Biopharmaceuticals, Inc., a publicly traded company in its early stages. Under his leadership as the Chief Financial Officer and Chief Operating Officer, the company’s capital funding has increased from $1.5 million to over $50 million.
Contact Details
Tags
peter culpepperpv-10cancerprovectus biopharmaceuticalsmelanomamedicalmedicinepete culpepperbreast cancercertified public accountantmetastatic melanomaresponsibilitiescorporate controllercpafinancebusinessprofit and lossamerican cancer societychief financial officercfocancer immunologyuniversity of marylandfinancial times listrankingmba programpotential treatmentcolon cancergradingbraindoctorsnew patentprovectustreating melanomakids ridespan-mass challengecancers of the skinworld congresssociety for immunotherapycancer presentation
Experienced in an array of financial and administrative matters, Peter Culpepper facilitates the growth of Provectus Biopharmaceuticals, Inc., a publicly traded company in its early stages. Under his leadership as the Chief Financial Officer and Chief Operating Officer, the company’s capital funding has increased from $1.5 million to over $50 million.
Tags
peter culpepperpv-10cancerprovectus biopharmaceuticalsmelanomamedicalmedicinepete culpepperbreast cancercertified public accountantmetastatic melanomaresponsibilitiescorporate controllercpafinancebusinessprofit and lossamerican cancer societychief financial officercfocancer immunologyuniversity of marylandfinancial times listrankingmba programpotential treatmentcolon cancergradingbraindoctorsnew patentprovectustreating melanomakids ridespan-mass challengecancers of the skinworld congresssociety for immunotherapycancer presentation
